TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10734752
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant or antiplatelet agents
Study: 1534176
Drug: Ondansetron (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (12 mg orally over 24 h)
Study: 1534176
Drug: Amphetamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (15 mg orally)
Study: 24388868
Drug: Budesonide/formoterol (BUD/FM;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (BUD/FM; Symbicort(®)) for maintenance and reliever therapy (SMART group, n=15)
Study: 18403271
Drug: 10% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% mannitol iv in 1 L 0.9% NaCL for 4 hours for 5 consecutive days
Study: 16185958
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with porfimer sodium (PORPDT) plus omeprazole
Study: 9182115
Drug: Netivudine 200
Normalized name: Netivudine
DrugBank: Netivudine (DB12606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netivudine 200 mg twice daily
Study: 9182115
Drug: Netivudine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netivudine (50 mg and 100 mg doses also tested)
Study: 9182115
Drug: Netivudine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netivudine (all doses)
Study: 1431261
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (AP)
Study: 1431261
Drug: Acellular diphtheria
Normalized name: acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Boostrix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular diphtheria and tetanus toxoids pertussis vaccine (ADTP)
Study: 6715565
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 and 975 mg, q.i.d.)
Study: 18481035
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg l-amphetamine
Study: 24042024
Drug: Non-aspirin NSAIDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin NSAIDs
Study: 22412170
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rTMS and tDCS
Study: 19254210
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg/day (n=13)
Study: 1735830
Drug: IVIG infusions
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG infusions
Study: 9647022
Drug: 2-day quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day quadruple therapy (omeprazole 40 mg b.i.d., amoxicillin 2.5 g once daily, metronidazole 500 mg t.i.d., bismuth subcitrate 360 mg t.i.d. for 2 days, followed by omeprazole 20 mg once daily for 6 additional days)
Study: 9647022
Drug: 2-day quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day quadruple therapy (per-protocol analysis)
Study: 29071915
Drug: Medication (Budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Budesonide Powder)
Study: 23410885
Drug: 40,000 IU/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40,000 IU/week oral vitamin D3 for 12 weeks
Study: 14985215
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg zeaxanthin
Study: 14985215
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zeaxanthin
Study: 14985215
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg and 10 mg zeaxanthin
Study: 15716329
Drug: Olmesartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (40 mg)
Study: 22653382
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly for 12 weeks (placebo/etanercept group)
Study: 16103252
Drug: Monitoring group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring group with no therapy in the slow VT zone
Study: 11815318
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid (FA) 400 microg daily
Study: 1932612
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg SR oxprenolol once every 24 h
Study: 1932612
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg RR oxprenolol once every 12 h
Study: 31611499
Drug: Nicardipine intraluminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine intraluminal administration in group A (no-touch SVG)
Study: 31611499
Drug: Nicardipine intraluminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine intraluminal administration in group B (conventional preparation)
Study: 11469941
Drug: Pre-packed chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-packed chloroquine tablets
Study: 11469941
Drug: Chloroquine syrup
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine syrup
Study: 10077773
Drug: SBT/ABPC 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBT/ABPC 3 g i.v., b.i.d.
Study: 10077773
Drug: CTM 1
Normalized name: CTM 1MG/P-EPHRINE 15MG CHEW TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTM 1 g i.v., b.i.d.
Study: 3258429
Drug: High voltage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High voltage electrical stimulation (daily from a commercial high voltage generator)
Study: 31867616
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral cyclic antibiotic (WOCA) prophylaxis
Study: 28481241
Drug: Galunisertib monotherapy
Normalized name: sapanisertib
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galunisertib monotherapy
Study: 28481241
Drug: Lomustine monotherapy
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine monotherapy
Study: 26202881
Drug: Melatonin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin supplementation (2 mg for 4 consecutive nights)
Study: 23787118
Drug: Synbiotic yogurt
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic yogurt (200 g/day)
Study: 18155491
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide (Ca(OH)2) placement after irrigation with 3 mL 17% EDTA and 10 mL 6% sodium hypochlorite (NaOCl)
Study: 18155491
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group irrigated with 10 mL 0.9% saline
Study: 18155491
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group irrigated with 10 mL 6% sodium hypochlorite (NaOCl)
Study: 17063640
Drug: Reference ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference ibuprofen preparation (400 mg)
Study: 14668079
Drug: High-dose labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose labetalol (200 mg)
Study: 14668079
Drug: Low-dose labetalol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose labetalol (100 mg)
Study: 20973706
Drug: Medication satisfaction,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication satisfaction, ADHD symptoms, and HRQL
Study: 17662509
Drug: Normal hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal hospital diet plus 400 mL oral nutritional supplements (106 subjects)
Study: 16325695
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (epirubicin, cyclophosphamide, and thiotepa supported by peripheral-blood progenitors)
Study: 16325695
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (four cycles of epirubicin and cyclophosphamide followed by three cycles of accelerated cyclophosphamide, methotrexate, and fluorouracil)
Study: 9642605
Drug: Antibiotics (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (amoxicillin and erythromycin)
Study: 793404
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone phosphate 0.1% eyedrops, five times daily for two weeks
Study: 793404
Drug: Placebo eyedrops,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eyedrops, five times daily for two weeks
Study: 31651246
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2.5 ml of hyperbaric bupivacaine 0.5% + 0.5 ml normal saline)
Study: 25292351
Drug: Fluoxetine (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (acute dose)
Study: 23649281
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-orthodontic treatment)
Study: 20021921
Drug: Low-dose amlodipine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amlodipine + diuretics (group A)
Study: 20021921
Drug: Low-dose amlodipine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amlodipine + telmisartan (group T)
Study: 16999566
Drug: Drug-related problems
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related problems (DRPs) identified using a hospital adaptation of Dader's method
Study: 14511080
Drug: Brief psychodynamic-interpersonal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychodynamic-interpersonal therapy (PIT)
Study: 19680137
Drug: ACEIs treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEIs treatment for 6 weeks
Study: 11895281
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing with 4 subgingival doses of minocycline microspheres over a 6-month period (RP/M)
Study: 7781496
Drug: Insulin treated
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treated diabetes
Study: 73062
Drug: (+)-cyanidanol-3 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-cyanidanol-3 (2 g/day)
Study: 31839392
Drug: Traditional skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional skin preparation
Study: 17373187
Drug: Biologic agents
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic agents
Study: 15253689
Drug: Conventional systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional systemic treatments
Study: 26626430
Drug: IPX066 245-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 245-mg LD capsules under fasting conditions
Study: 26626430
Drug: IPX066 245-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 245-mg LD capsules sprinkled on applesauce
Study: 26626430
Drug: IPX066 245-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 245-mg LD capsules after a high-fat, high-calorie meal
Study: 20960003
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg scopolamine (intravenous)
Study: 20960003
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg mecamylamine (max. 15 mg; oral)
Study: 1534476
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen
Study: 31790890
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g α-lipoic acid (ALA) daily for 6 months
Study: 17259696
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ALA treatment)
Study: 24295024
Drug: Tailored Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored Cognitive-Behavioral Therapy (TCBT)
Study: 24295024
Drug: Standard Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Cognitive-Behavioral Therapy (SCBT)
Study: 17662554
Drug: Mouthwash oral-throat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash oral-throat rinses
Study: 17662554
Drug: Water oral-throat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water oral-throat rinses
Study: 15812256
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg od + Hydrochlorothiazide 12.5 mg
Study: 15812256
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg od + Hydrochlorothiazide 25 mg
Study: 6870216
Drug: Intranasal enviroxime,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal enviroxime, given 6 times a day
Study: 6870216
Drug: Intranasal enviroxime
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal enviroxime (in volunteers without symptoms at the start of medication)
Study: 23185762
Drug: Yiqi Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Huoxue Qufeng Decoction (YHQD), one dose daily, once in the morning and once in the evening for 8 weeks
Study: 23185762
Drug: Fuyang Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuyang Granule (FYG), 6 g each time, three times daily for 8 weeks
Study: 15675986
Drug: L3/4T group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L3/4T group (4 mg hyperbaric bupivacaine, head-down tilt)
Study: 15675986
Drug: L2/3 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L2/3 group (4 mg hyperbaric bupivacaine, horizontal)
Study: 15675986
Drug: L3/4H group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L3/4H group (4 mg hyperbaric bupivacaine, horizontal)
Study: 17326150
Drug: Lactulose treatment
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose treatment for 3 months (n=31)
Study: 17326150
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n=30)
Study: 30146446
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (0.9% sodium chloride)
Study: 7979616
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (500 cGy)
Study: 7979616
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative therapy
Study: 3055924
Drug: Nifedipine-propranolol combination
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine-propranolol combination therapy
Study: 3055924
Drug: Diltiazem-propranolol combination
Normalized name: propranolol and other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem-propranolol combination therapy
Study: 4808815
Drug: Long-term aspirin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term aspirin and prednisone (patients)
Study: 25155895
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy monitoring (DTMG)
Study: 21477065
Drug: GMP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMP (1 or 2 mg glimepiride, 500 mg sustained-release metformin, and 15 mg pioglitazone administered once daily)
Study: 21477065
Drug: IM (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM (human insulin 70/30 mix and 500 mg sustained-release metformin administered twice daily)
Study: 18094223
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate hydrofluoroalkane 88 mug twice a day
Study: 18094223
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate chlorofluorocarbon 88 mug twice a day
Study: 6086466
Drug: WHO recommended
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [WHO Recommended Hand Rub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO recommended oral rehydration solution containing 2.5 g sodium bicarbonate per litre
Study: 6086466
Drug: Both sodium
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sodium citrate and sodium bicarbonate solutions
Study: 21770835
Drug: Early high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high doses parenteral nutrition (3.0 g/kg/day amino acids and 3 g/kg/day of 20% lipid)
Study: 21770835
Drug: Early low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early low dose parenteral nutrition (1 g/kg/day amino acids and lipid, advanced to 3 g/kg/day over 3 days)
Study: 11897906
Drug: Antiphospholipid antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiphospholipid antibodies (aPL) presence in women undergoing IVF‐ET
Study: 9834049
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral ibuprofen 30 minutes before surgery
Study: 8077892
Drug: Antacid solution
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid solution
Study: 15864218
Drug: l-NMMA (NO-synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-NMMA (NO-synthase inhibitor)
Study: 16401307
Drug: Cerivastatin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.4 mg/day)
Study: 10759665
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ciprofloxacin (500 mg) and tinidazole (600 mg)
Study: 10759665
Drug: Ciprofloxacin-tinidazole combination
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin-tinidazole combination twice a day for 3 days
Study: 8628089
Drug: Benzalkonium chloride
Normalized name: Benzalkonium Chloride
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzalkonium chloride nasal spray
Study: 1466465
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg morphine sulfate and 100 micrograms epinephrine in normal saline (group 3)
Study: 26694939
Drug: Ondansetron 4 mg
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 4 mg intravenously
Study: 20200816
Drug: L-methionine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-methionine (0.1 g/kg)
Study: 18991518
Drug: T'ai chi
Approvals — FDA: no, EMA: no, PMDA: no
Description: T'ai chi (TC) exercise, 90-minute sessions weekly for 9 months
Study: 17179461
Drug: Antiarrhythmic medications
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic medications
Study: 9917122
Drug: β-blockers or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers or verapamil
Study: 27464316
Drug: Antidepressant use
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant use
Study: 20502133
Drug: Tolcapone (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (as an adjunct to l-dopa)
Study: 29653649
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg BID
Study: 24911432
Drug: BID dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID dosing regimen vs edoxaban QD
Study: 24911432
Drug: Non-vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vitamin K antagonist oral anticoagulants vs warfarin
Study: 27813398
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg/week
Study: 15692829
Drug: Theophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (6 mg kg (‐1) body weight) intravenously
Study: 10215747
Drug: Selegiline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (5 mg, 10 mg, 20 mg, 40 mg) with oral contraceptives
Study: 10215747
Drug: Selegiline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (5 mg, 10 mg, 20 mg, 40 mg) without oral contraceptives
Study: 2601986
Drug: Oxybutynin chloride
Normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin chloride and verapamil combination
Study: 778564
Drug: Gaviscon (alginate/alginic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaviscon (alginate/alginic acid plus antacid)
Study: 204058
Drug: Standard antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antacid
Study: 17145854
Drug: HPV16 L2E7E6
Normalized name: Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7
DrugBank: Verpasep caltespen (DB04959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 L2E7E6 vaccine (533-mug) administered thrice at monthly intervals to healthy volunteers
Study: 11310378
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g/day for 3 months)
Study: 8878600
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin (7.5 mg.kg of body weight‐1 given over 30 min)
Study: 8878600
Drug: Intravenous ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ofloxacin (7.5 mg.kg of body weight‐1)
Study: 1725032
Drug: Ramipril monotherapy
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril monotherapy (1.25-10 mg/day)
Study: 1725032
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg/day) plus piretanide (3 mg/day)
Study: 2861527
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg/day)